References:
1. McKenna RW, Kyle RA, Kuehl WM, Harris NL, Coupland RW, Fend F. Plasma cell neoplasms. En Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. editores. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon FWHOC of T of H and LT 2017., Swerdlow SH, Campo E, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France .; 2017. doi:10.1017/CBO9781107415324.004
2. Nalesnik MA. Plasma cell tumors In transplant patients. Blood . 2013;121(8):1247-1249. doi:10.1182/blood-2013-01-475947
3. Opelz G, Henderson R. Incidence of non-hodgkin lymphoma in kidney and heart transplant recipients. Lancet . 1993;342(8886-8887):1514-1516. doi:10.1016/S0140-6736(05)80084-4
4. Opelz G, Döhler B. Lymphomas after Solid Organ Transplantation: A Collaborative Transplant Study Report. Am J Transplant . 2004;4(2):222-230. doi:10.1046/j.1600-6143.2003.00325.x
5. Mynarek M, Schober T, Behrends U, Maecker-Kolhoff B. Posttransplant lymphoproliferative disease after pediatric solid organ transplantation.Clin Dev Immunol . 2013;2013. doi:10.1155/2013/814973
6. West SC, Friedland-Little JM, Schowengerdt KO, et al. Characteristics, risks, and outcomes of post-transplant lymphoproliferative disease >3 years after pediatric heart transplant: A multicenter analysis. Clin Transplant . 2019;33(5):1-8. doi:10.1111/ctr.13521
7. Perry AM, Aoun P, Coulter DW, Sanger WG, Grant WJ, Coccia PF. Early onset, EBV- PTLD in pediatric liver-small bowel transplantation recipients: A spectrum of plasma cell neoplasms with favorable prognosis. Blood . 2013;121(8):1377-1383. doi:10.1182/blood-2012-06-438549
8. Short SRP, Cook SL, Kim AS, Lamour JM, Lowe EJ, Petersen WC. Plasmacytoma-like posttransplant lymphoproliferative disorder in a pediatric heart transplant recipient. J Pediatr Hematol Oncol . 2016;38(2):e71-e74. doi:10.1097/MPH.0000000000000501
9. Xue L, Zuppan C, Wang T, Kheradpour A, Rowsell EH, Wang J. Plasma Cell Myeloma Type Posttransplant Lymphoproliferative Disorder in an 18-Month-Old Heart Transplant Recipient: Case Report and Review of the Literature. J Pediatr Hematol Oncol . 2020;42(3):e170-e173. doi:10.1097/MPH.0000000000001510
10. Yang CH, Gombar S, Twist CJ, Gratzinger D, Esquivel CO, Lau AH. hyperviscosity syndrome in a child after liver transplant. 2017;64(6):2250-2252. doi:10.1002/hep.28657.Plasmacytoid
11. Epperly R, Ozolek J, Soltys K, Cohen D, Goyal R, Friehling E. Treatment of pediatric plasma cell myeloma type post-transplant lymphoproliferative disorder with modern risk-directed therapy.Pediatr Blood Cancer . 2018;65(10):4-7. doi:10.1002/pbc.27283
12. Plant AS, Venick RS, Farmer DG, Upadhyay S, Said J, Kempert P. Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients.Pediatr Blood Cancer . 2013. doi:10.1002/pbc.24632
13. Tcheng WY, Said J, Hall T, Al-Akash S, Malogolowkin M, Feig SA. Post-transplant multiple myeloma in a pediatric renal transplant patient. Pediatr Blood Cancer . 2006. doi:10.1002/pbc.20482
14. Zuckerman WA, Zeevi A, Mason KL, et al. Study rationale, design, and pretransplantation alloantibody status: A first report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric heart transplantation. Am J Transplant . 2018. doi:10.1111/ajt.14695
15. Barth Syndrome - NORD (National Organization for Rare Disorders). https://rarediseases.org/rare-diseases/barth-syndrome/.
16. Galera P, Flavin R, Savage NM, et al. Epstein-Barr Virus-negative Marginal Zone Lymphoma as an Uncommon Form of Monomorphic Posttransplant Lymphoproliferative Disorder. Am J Surg Pathol . 2020;44(10):1340-1352. doi:10.1097/PAS.0000000000001514
17. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol . 2019;185(3):492-502. doi:10.1111/bjh.15806
18. Iannitto E, Bellei M, Amorim S, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol . 2018;183(5):755-765. doi:10.1111/bjh.15641
19. Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol . 2018;93(8):1091-1110. doi:10.1002/ajh.25117
20. Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med . 2019. doi:10.1056/nejmoa1817249